Perrigo Reports Decline in Q2 2026 Financial Performance with $1,022.8M in Net Sales

Perrigo Company plc reported a decline in financial performance for the second quarter of 2026, with net sales of $1,022.8 million, down 3.2% from $1,056.3 million in the same period last year. The company's gross profit also decreased to $313.9 million, representing a gross margin of 30.7%, compared to 34.4% in the prior year. Operating income fell significantly to $23.5 million from $45.4 million, reflecting a 48.4% decrease. The decline in revenue was attributed primarily to lower retailer inventory levels and soft consumption in the Self Care segment, as well as the impact of the divestiture of the Dermacosmetics Business, which was completed in April 2026.

For the first half of 2026, Perrigo's net sales totaled $1,992.0 million, a decrease of 5.2% from $2,100.2 million in the same period of 2025. The company reported an operating loss of $348.9 million, a stark contrast to the operating income of $92.3 million recorded in the previous year. This significant decline was largely driven by a $331.8 million goodwill impairment charge, alongside lower gross profit due to decreased sales volumes and planned under-absorption from prior-year sales.

Strategically, Perrigo completed the sale of its Dermacosmetics Business for $362.9 million, which resulted in a pre-tax gain of $129.5 million. The divestiture is part of the company's ongoing efforts to streamline operations and focus on its core self-care segments. Additionally, the company has initiated several restructuring programs, including the Supply Chain Reinvention Program and Project Energize, aimed at reducing costs and enhancing operational efficiency. These initiatives are expected to yield annualized savings of approximately $157 million and $167 million, respectively.

Operationally, Perrigo's Self Care segment reported net sales of $576.6 million, down from $598.6 million, while the Specialty Care segment saw a slight decrease to $226.6 million from $233.1 million. The Infant Formula segment, however, experienced growth, with sales rising to $100.9 million from $82.0 million, driven by increased contract shipments. The company continues to face challenges in the market, including inflationary pressures and supply chain disruptions, which have impacted production and profitability.

Looking ahead, Perrigo's management remains cautious due to ongoing macroeconomic uncertainties, including inflation, geopolitical tensions, and regulatory changes. The company is focused on stabilizing its operations and enhancing cash flow while navigating these challenges. The outlook for the remainder of the year will depend on the effectiveness of its strategic initiatives and the overall market conditions.